Healthcare / Medical DevicesTokyo
$250.00
-2.00 (-0.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-162.0M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.1%
↓Gross Margin
23.9%
↓Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-24.6%
FCF CAGR
—
FCF margin
-3.3%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.98B · net income $-1.12B · FCF $-130.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.98B | $3.98B | $5.28B | $7.43B | $9.30B |
| Net Income | $-1.12B | $-1.12B | $-1.32B | $45.3M | $796.0M |
| EBITDA | $-661.8M | $-661.8M | $-594.1M | $740.3M | $1.16B |
| EPS | -40.59 | -40.59 | -47.93 | 1.64 | 29.10 |
| Gross Margin | 23.9% | 23.9% | 25.6% | 33.5% | 33.3% |
| Operating Margin | -24.0% | -24.0% | -21.1% | 2.0% | 9.6% |
| Net Margin | -28.2% | -28.2% | -25.1% | 0.6% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.74 | 0.62 | 0.56 |
| Current Ratio | 2.50 | 2.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-130.8M | $-130.8M | $-162.0M | $-1.38B | $-2.09B |
| Returns | |||||
| ROE | -27.1% | -27.1% | -25.4% | 0.7% | 12.1% |
| Valuation | |||||
| P/E | — | — | — | 350.61 | 28.38 |
| EV/EBITDA | — | — | — | 23.16 | 19.38 |
| P/B | 1.67 | 1.67 | 1.86 | 2.44 | 3.47 |
| Growth & Yield | |||||
| Revenue Growth | -24.6% | -24.6% | -29.0% | -20.1% | — |
| EPS Growth | 15.3% | 15.3% | -3022.6% | -94.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-47.93 → -40.59
Residual
+23.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.